Wells Fargo & Company Acorda Therapeutics Inc Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.55 - $1.0 $1 - $2	2 Added 0.0%	74,750 $44,000
Q4 2022 Feb 13, 2023	BUY	$0.52 - $0.77 $2 - $3	5 Added 0.01%	74,748 $57,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.53 $20 - $38	72 Added 0.1%	74,743 $22,000
Q2 2022 Aug 12, 2022	BUY	$0.3 - $1.67 $7,438 - $41,409	24,796 Added 49.72%	74,671 $35,000
Q1 2022 May 16, 2022	BUY	$1.61 - $2.5 $1 - $2	1 Added 0.0%	49,875 $80,000
Q4 2021 Feb 14, 2022	BUY	$2.3 - $4.71 $114,268 - $234,002	49,682 Added 25876.04%	49,874 $119,000
Q3 2021 Nov 15, 2021	SELL	$3.36 - $4.79 $10 - $14	-3 Reduced 1.54%	192 $1,000
Q1 2021 May 13, 2021	BUY	$3.8 - $8.04 $741 - $1,567	195 New	195 $1,000

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.